Brian Skorney Analyst Performance

Senior Research Analyst at Robert W. Baird

Brian Skorney is a stock analyst at Robert W. Baird focused in the medical sector, covering 29 publicly traded companies. Over the past year, Brian Skorney has issued 12 stock ratings, including buy and hold recommendations. While full access to Brian Skorney's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Brian Skorney's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Analyst Rating

Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat

Average Return

00.00% 12-Month ROI

Success Rate

00.00% Profitable Ratings

Total Ratings

176 Last 11 Years

Buy Recommendations

69.71% 122 Buy Ratings

Companies Covered

29 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	69.7%	122 ratings
Hold	25.7%	44 ratings
Sell	4.6%	8 ratings

Out of 175 total stock ratings issued by Brian Skorney at Robert W. Baird, the majority (69.7%) have been Buy recommendations, followed by 25.7% Hold and 4.6% Sell.

Best & Worst Calls

• Best Call

  0000.0%

  SRPT

  Apr 2017

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.
• Worst Call

  000.0%

  MLNT

  Aug 2016

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	93.1% of companies on NASDAQ	27 companies
NYSE	6.9% of companies on NYSE	2 companies

Brian Skorney, an analyst at Robert W. Baird, currently covers 29 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 27 companies	93.1%
	Aerospace 1 company	3.4%
	Miscellaneous 1 company	3.4%

Brian Skorney of Robert W. Baird specializes in stock coverage within the Medical sector, with additional focus on Aerospace and companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 12 companies	41.4%
PHARMACEUTICAL PREPARATIONS 8 companies	27.6%
MED - DRUGS 5 companies	17.2%
BIOTECHNOLOGY 1 company	3.4%
MED - GENERIC DRG 1 company	3.4%
AEROSP/DEF EQ 1 company	3.4%
Miscellaneous 1 company	3.4%

About Brian Skorney

Brian Skorney is a Baird Senior Research Analyst covering Biotechnology. Prior to joining Baird in 2012, he was a senior vice president in equity research at Brean Murray Carrett & Co, a vice president in equity research at ThinkEquity, LLC and a research analyst at Susquehanna International Group, LLC, all in the biotech/pharmaceutical industry. He also worked as a coordinator and lab manager at the Howard Hughes Medical Institute. Brian was ranked by TipRanks as No. 75 on the Top 100 Wall Street analysts of 2019 list. In 2016, he was ranked by Thomson Reuters Analyst Awards (StarMine) as the No. 3 stock picker in Biotechnology. Brian received a BS in Biological Sciences from the University of Notre Dame and an MBA in Finance from New York University.

Brian Skorney's Ratings History at Robert W. Baird

Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe

Start Date

End Date

All Ratings Strong Buy Buy Hold Sell Rating

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription

12-Month ROIUpgrade to All Access to use the All ROI Filter

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating	12-Month Price & ROI	Details
BHVN Biohaven	8/12/2025	Lower Price Target	$13.42	$52.00	Outperform	$0.00 00.00% ROI
SRPT Sarepta Therapeutics	7/17/2025	Boost Price Target	$18.38	$35.00	Outperform	$0.00 00.00% ROI
SLNO Soleno Therapeutics	7/11/2025	Set Price Target	$80.32	$121.00	Outperform	$0.00 00.00% ROI
DYN Dyne Therapeutics	6/18/2025	Lower Price Target	$10.81	$32.00	Outperform	$0.00 00.00% ROI
SRPT Sarepta Therapeutics	6/17/2025	Lower Price Target	$21.28	$30.00	Outperform	$0.00 00.00% ROI
SLNO Soleno Therapeutics	5/8/2025	Boost Price Target	$74.66	$105.00	Outperform	$0.00 00.00% ROI
BIIB Biogen	5/2/2025	Lower Price Target	$120.93	$255.00	Outperform	$0.00 00.00% ROI
BHVN Biohaven	4/28/2025	Lower Price Target	$19.81	$57.00	Outperform	$0.00 00.00% ROI
REGN Regeneron Pharmaceuticals	4/25/2025	Lower Price Target	$599.76	$652.00	Neutral	$0.00 00.00% ROI
SLNO Soleno Therapeutics	3/27/2025	Boost Price Target	$48.97	$102.00	Outperform	$0.00 00.00% ROI
MIRM Mirum Pharmaceuticals	2/27/2025	Boost Price Target	$50.52	$55.00	Outperform	$0.00 00.00% ROI
REGN Regeneron Pharmaceuticals	2/5/2025	Lower Price Target	$722.27	$759.00	Neutral	$0.00 00.00% ROI

Stock Forecasts and Research Tools

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.